Welcome to Aleta Biotherapeutics

Aleta Biotherapeutics develops unique cell therapy solutions for all cancers.

Who We Are

Aleta Biotherapeutics is an immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, including currently intractable solid tumors.

The company was founded by Paul Rennert and Roy Lobb, who bring extensive scientific and leadership experience in immunology, oncology and drug development to this new enterprise. Aleta Bio has created a unique portfolio of multi-antigen targeting solutions for cell therapy, designed to address the critical issues of CAR-T persistence, tumor antigen loss leading to patient relapse, and tumor antigen heterogeneity.

Latest News

Aleta Biotherapeutics Presents In Vivo Results of a Novel Therapeutic Designed to Reactivate CAR T Cells in Patients Who Relapse After CAR T Therapy

Aleta Biotherapeutics today presented in vitro and in vivo results demonstrating that Aleta’s novel CD19-anti-CD20 bridging protein prevents and reverses CD19-negative relapse from CAR-CD19 T cell treatment.

“FDA-approved CAR-CD19 T cell therapies such as tisagenlecleucel and axicabtagene ciloleucel have demonstrated remarkable success in treating B cell cancers including refractory and relapsed acute lymphoblastic leukemia and non-Hodgkin lymphoma. However, relapse rates of up to 50% have been reported, most occurring within 6 months of CAR-CD19 T cell therapy. Some patients relapse due to the loss of expression of CD19 on tumor cells and other patients relapse because the cell therapy has failed to fully control tumor cell proliferation,” said Paul Rennert, Ph.D., President and Chief Scientific Officer, Aleta Biotherapeutics.

Get In Touch

Send message